Atrophy rates in asymptomatic amyloidosis: implications for Alzheimer prevention trials
about
Ushering in the study and treatment of preclinical Alzheimer diseaseMemory loss in Alzheimer's diseaseStudy protocol: Insight 46 - a neuroscience sub-study of the MRC National Survey of Health and Development.Cerebrospinal fluid markers including trefoil factor 3 are associated with neurodegeneration in amyloid-positive individuals.The intersection of amyloid beta and tau at synapses in Alzheimer's diseaseAmyloid burden in cognitively normal elderly is associated with preferential hippocampal subfield volume loss.The effect of amyloid pathology and glucose metabolism on cortical volume loss over time in Alzheimer's diseaseIs amyloid-β harmful to the brain? Insights from human imaging studiesMultimodal MRI-based Imputation of the Aβ+ in Early Mild Cognitive Impairment.Outcomes Assessment in Clinical Trials of Alzheimer's Disease and its Precursors: Readying for Short-term and Long-term Clinical Trial Needs.Biomarker modelling of early molecular changes in Alzheimer's disease.Enabling a multidisciplinary approach to the study of ageing and Alzheimer's disease: an update from the Australian Imaging Biomarkers and Lifestyle (AIBL) study.Dementia risk and prevention by targeting modifiable vascular risk factors.Amyloid-β deposition and regional grey matter atrophy rates in dementia with Lewy bodiesKIBRA is associated with accelerated cognitive decline and hippocampal atrophy in APOE ε4-positive cognitively normal adults with high Aβ-amyloid burden.Cortical β-amyloid burden, gray matter, and memory in adults at varying APOE ε4 risk for Alzheimer's disease.Human Apolipoprotein E Genotype Differentially Affects Olfactory Behavior and Sensory Physiology in Mice.
P2860
Q27014791-531ED289-AEDF-4A9B-8F8A-E65A894F1CB6Q27687485-5537D61A-FF92-4F1B-8732-FAF585E23FE7Q33576727-52F00E4F-C130-4038-831F-103241B74142Q33990663-35BD12A4-0CE2-4B74-9B76-5D0D8A9CEF19Q34054680-686E754F-9607-4AF1-95D7-8DE45D3DFF1DQ35152147-DB77E86B-699C-4675-ACE4-F2B8B3E8987FQ37029599-89F98299-14DF-4F41-8898-CAF1C52DA690Q37188315-35A95B7B-54F7-4DD6-BC66-089A28BF2511Q37694011-FB6D0900-07AB-4BBF-A647-1DA7716CC641Q37730520-7F35D778-82E0-4532-9AE5-1B5FE37E4F3BQ38166669-55AF0CAA-2994-47F4-820F-EAAFE240EBA8Q38178373-45E5B2FA-AA56-4BA0-8FBC-F349348FA1A4Q38653373-87D216AF-534C-4693-81B8-4013B0A039A7Q41635671-1696AD80-D99E-46AA-BC96-112B2334107BQ47549663-77264D81-E661-4D88-9FBB-1945E405D185Q47716549-DAEDA4BD-D9FF-4B3C-AF84-5929D298EAF6Q52573559-291FDD51-A150-43CE-884A-C51BFB217606
P2860
Atrophy rates in asymptomatic amyloidosis: implications for Alzheimer prevention trials
description
2013 nî lūn-bûn
@nan
2013 թուականին հրատարակուած գիտական յօդուած
@hyw
2013 թվականին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Atrophy rates in asymptomatic amyloidosis: implications for Alzheimer prevention trials
@ast
Atrophy rates in asymptomatic amyloidosis: implications for Alzheimer prevention trials
@en
Atrophy rates in asymptomatic amyloidosis: implications for Alzheimer prevention trials
@nl
type
label
Atrophy rates in asymptomatic amyloidosis: implications for Alzheimer prevention trials
@ast
Atrophy rates in asymptomatic amyloidosis: implications for Alzheimer prevention trials
@en
Atrophy rates in asymptomatic amyloidosis: implications for Alzheimer prevention trials
@nl
prefLabel
Atrophy rates in asymptomatic amyloidosis: implications for Alzheimer prevention trials
@ast
Atrophy rates in asymptomatic amyloidosis: implications for Alzheimer prevention trials
@en
Atrophy rates in asymptomatic amyloidosis: implications for Alzheimer prevention trials
@nl
P2093
P2860
P50
P1433
P1476
Atrophy rates in asymptomatic amyloidosis: implications for Alzheimer prevention trials
@en
P2093
Australian Imaging Biomarkers, Lifestyle Flagship Study of Ageing
Christopher C Rowe
Jonathan M Schott
K Abigail Andrews
Kate E Macdonald
Kelvin K Leung
Marc Modat
Tom Yeatman
Victor L Villemagne
P2860
P304
P356
10.1371/JOURNAL.PONE.0058816
P407
P577
2013-03-15T00:00:00Z